Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs
October 13th 2023Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
July 10th 2023In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcare
March 10th 2023How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?
Focus and Fundamentals: CFO Strategies on the Journey to Commercialization
February 9th 2023Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
January 11th 2023As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.